JP2010525056A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525056A5
JP2010525056A5 JP2010506133A JP2010506133A JP2010525056A5 JP 2010525056 A5 JP2010525056 A5 JP 2010525056A5 JP 2010506133 A JP2010506133 A JP 2010506133A JP 2010506133 A JP2010506133 A JP 2010506133A JP 2010525056 A5 JP2010525056 A5 JP 2010525056A5
Authority
JP
Japan
Prior art keywords
compound according
alkoxy
pharmaceutically acceptable
monosubstituted
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525056A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2008/050459 external-priority patent/WO2008130320A2/en
Publication of JP2010525056A publication Critical patent/JP2010525056A/ja
Publication of JP2010525056A5 publication Critical patent/JP2010525056A5/ja
Pending legal-status Critical Current

Links

JP2010506133A 2007-04-23 2008-04-22 新規化合物 Pending JP2010525056A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23
PCT/SE2008/050459 WO2008130320A2 (en) 2007-04-23 2008-04-22 Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2010525056A JP2010525056A (ja) 2010-07-22
JP2010525056A5 true JP2010525056A5 (cg-RX-API-DMAC7.html) 2012-06-07

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506133A Pending JP2010525056A (ja) 2007-04-23 2008-04-22 新規化合物

Country Status (23)

Country Link
US (2) US8143408B2 (cg-RX-API-DMAC7.html)
EP (1) EP2158198B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010525056A (cg-RX-API-DMAC7.html)
KR (1) KR20100015827A (cg-RX-API-DMAC7.html)
CN (1) CN101687860B (cg-RX-API-DMAC7.html)
AR (1) AR066266A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008241610B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810354A2 (cg-RX-API-DMAC7.html)
CA (1) CA2685141A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008001170A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251361A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP099706A (cg-RX-API-DMAC7.html)
IL (1) IL201309A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009011364A (cg-RX-API-DMAC7.html)
MY (1) MY146662A (cg-RX-API-DMAC7.html)
NZ (1) NZ581353A (cg-RX-API-DMAC7.html)
PE (1) PE20090727A1 (cg-RX-API-DMAC7.html)
RU (1) RU2460730C2 (cg-RX-API-DMAC7.html)
SA (1) SA08290245B1 (cg-RX-API-DMAC7.html)
TW (1) TW200848037A (cg-RX-API-DMAC7.html)
UY (1) UY31046A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008130320A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907137B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2942346B1 (en) 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
CN106117213B (zh) * 2009-10-26 2022-03-18 西格诺药品有限公司 杂芳基化合物及其合成和纯化方法
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JPWO2011093501A1 (ja) 2010-02-01 2013-06-06 日本ケミファ株式会社 Gpr119作動薬
AU2011293612B2 (en) * 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102603659B (zh) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
AU2014212426B8 (en) * 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
US10227338B2 (en) 2015-11-13 2019-03-12 Daewoong Pharmaceutical Co., Ltd. Substituted benzenesulfonamides as sodium channel blockers
CN105541774B (zh) * 2016-01-13 2018-06-15 华中师范大学 3,4-二氢香豆素类化合物及其制备方法和用途
PL3615527T3 (pl) * 2017-06-30 2024-07-01 Elanco Animal Health Gmbh Nowe pochodne azachinoliny
MX2020007532A (es) 2018-01-19 2020-09-09 Cytokinetics Inc Inhibidores de sarcomero cardiaco.
AU2019232437A1 (en) 2018-03-07 2020-10-08 Bayer Aktiengesellschaft Identification and use of ERK5 inhibitors
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
KR102812440B1 (ko) 2018-09-10 2025-05-26 가껭세이야꾸가부시기가이샤 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス, インコーポレイテッド 心筋サルコメア阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (ja) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd アザクロマン誘導体及びその用途
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (ja) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd ポリフェノール化合物及びこれを含有する医薬
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
CA2539227A1 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
WO2006119451A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
US20090291983A1 (en) * 2006-07-12 2009-11-26 Astrazeneca Ab 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم

Similar Documents

Publication Publication Date Title
JP2010525056A5 (cg-RX-API-DMAC7.html)
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
JP2013542247A5 (cg-RX-API-DMAC7.html)
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2009514870A5 (cg-RX-API-DMAC7.html)
JP2013522326A5 (cg-RX-API-DMAC7.html)
JP2016040288A5 (cg-RX-API-DMAC7.html)
JP2013508279A5 (cg-RX-API-DMAC7.html)
JP2015523397A5 (cg-RX-API-DMAC7.html)
JP2012041349A5 (cg-RX-API-DMAC7.html)
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
RU2017105353A (ru) Соединения
JP2015503596A5 (cg-RX-API-DMAC7.html)
JP2014505107A5 (cg-RX-API-DMAC7.html)
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2016531126A5 (cg-RX-API-DMAC7.html)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
RU2011153353A (ru) Кетолидные соединения, обладающие противомикробной активностью
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
TNSN07419A1 (en) Methods for treating drug resistant cancer
JP2017529389A5 (cg-RX-API-DMAC7.html)
JP2015536974A5 (cg-RX-API-DMAC7.html)
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
JP2016520128A5 (cg-RX-API-DMAC7.html)